Plain-English translation of NCT05601700 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called letrozole—a hormone therapy pill taken daily—may work better than standard chemotherapy for treating advanced low-grade serous ovarian cancer. This type of cancer grows slowly and has receptors for hormones, which means it may respond to hormone-blocking treatment. Researchers want to see if this simpler daily pill approach could be more effective and easier to tolerate than traditional chemotherapy.
Current treatment for this rare ovarian cancer type relies on standard chemotherapy, which can have difficult side effects. Doctors have noticed that this cancer often has hormone receptors on its surface, suggesting it might respond well to hormone-blocking therapy instead—potentially offering patients a gentler option with better quality of life.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the daily hormone therapy pill (taken by mouth for up to 5 years or until your cancer returns) or standard intravenous chemotherapy (given every 3 weeks for 6–8 cycles). You will have regular medical appointments to check how you are responding, including blood tests, imaging scans, and quality-of-life questionnaires about pain and symptom burden. Researchers will also analyze your tumor tissue and blood samples to understand why the treatment works or doesn't work for you.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
Italy